<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:03:24Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5192817" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5192817</identifier><datestamp>2017-01-01</datestamp><setSpec>jcmmopen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Cell Mol Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Cell. Mol. Med</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1582-4934</journal-id>
      <journal-id journal-id-type="publisher-id">JCMM</journal-id>
      <journal-title-group>
        <journal-title>Journal of Cellular and Molecular Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1582-1838</issn>
      <issn pub-type="epub">1582-4934</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5192817</article-id>
      <article-id pub-id-type="pmcid">PMC5192817</article-id>
      <article-id pub-id-type="pmc-uid">5192817</article-id>
      <article-id pub-id-type="pmid">27599751</article-id>
      <article-id pub-id-type="pmid">27599751</article-id>
      <article-id pub-id-type="doi">10.1111/jcmm.12953</article-id>
      <article-id pub-id-type="publisher-id">JCMM12953</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Original Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>
<styled-content style="fixed-case">MXRA</styled-content>5 is a <styled-content style="fixed-case">TGF</styled-content>âÎ²1âregulated human protein with antiâinflammatory and antiâfibrotic properties</article-title>
      </title-group>
      <contrib-group>
        <contrib id="jcmm12953-cr-0001" contrib-type="author">
          <name>
            <surname>Poveda</surname>
            <given-names>Jonay</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm12953-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm12953-cr-0002" contrib-type="author">
          <name>
            <surname>Sanz</surname>
            <given-names>Ana B.</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm12953-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm12953-cr-0003" contrib-type="author">
          <name>
            <surname>FernandezâFernandez</surname>
            <given-names>Beatriz</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm12953-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm12953-cr-0004" contrib-type="author">
          <name>
            <surname>Carrasco</surname>
            <given-names>Susana</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm12953-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm12953-cr-0005" contrib-type="author">
          <name>
            <surname>RuizâOrtega</surname>
            <given-names>Marta</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm12953-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="jcmm12953-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="jcmm12953-cr-0006" contrib-type="author">
          <name>
            <surname>CannataâOrtiz</surname>
            <given-names>Pablo</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm12953-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm12953-cr-0007" contrib-type="author" corresp="yes">
          <name>
            <surname>Ortiz</surname>
            <given-names>Alberto</given-names>
          </name>
          <address>
            <email>aortiz@fjd.es</email>
          </address>
          <xref ref-type="aff" rid="jcmm12953-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="jcmm12953-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="jcmm12953-aff-0003">
<sup>3</sup>
</xref>
          <xref ref-type="author-notes" rid="jcmm12953-note-1001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="jcmm12953-cr-0008" contrib-type="author" corresp="yes">
          <name>
            <surname>SanchezâNiÃ±o</surname>
            <given-names>Maria D.</given-names>
          </name>
          <address>
            <email>mdsanchez@fjd.es</email>
          </address>
          <xref ref-type="aff" rid="jcmm12953-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="jcmm12953-note-1001">
<sup>â </sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="jcmm12953-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <institution>IISâFundacion Jimenez Diaz Universidad Autonoma de Madrid</institution>
        <institution>REDINREN</institution>
        <named-content content-type="city">Madrid</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="jcmm12953-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">School of Medicine</named-content>
        <institution>Universidad Autonoma de Madrid</institution>
        <named-content content-type="city">Madrid</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="jcmm12953-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <institution>Fundacion Renal IÃ±igo Alvarez de ToledoâIRSIN</institution>
        <named-content content-type="city">Madrid</named-content>
        <country country="ES">Spain</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Alberto ORTIZ.<break/>
Eâmail: <email>aortiz@fjd.es</email> Maria D. SANCHEZâNIÃO.<break/>
Eâmail: <email>mdsanchez@fjd.es</email><break/></corresp>
        <fn fn-type="equal" id="jcmm12953-note-1001">
          <label>â </label>
          <p>Both authors contributed equally.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>06</day>
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <volume>21</volume>
      <issue>1</issue>
      <issue-id pub-id-type="doi">10.1111/jcmm.2017.21.issue-1</issue-id>
      <fpage>154</fpage>
      <lpage>164</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>7</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JCMM-21-154.pdf"/>
      <abstract id="jcmm12953-abs-0001">
        <title>Abstract</title>
        <p>Current therapy for chronic kidney disease (<styled-content style="fixed-case">CKD</styled-content>) is unsatisfactory because of an insufficient understanding of its pathogenesis. Matrix remodellingâassociated protein 5 (<styled-content style="fixed-case">MXRA</styled-content>5, adlican) is a human protein of unknown function with high kidney tissue expression, not present in rodents. Given the increased expression of <styled-content style="fixed-case">MXRA</styled-content>5 in injured tissues, including the kidneys, we have suggested that <styled-content style="fixed-case">MXRA</styled-content>5 may modulate kidney injury. <styled-content style="fixed-case">MXRA</styled-content>5 immunoreactivity was observed in tubular cells in human renal biopsies and in urine from <styled-content style="fixed-case">CKD</styled-content> patients. We then explored factors regulating <styled-content style="fixed-case">MXRA</styled-content>5 expression and <styled-content style="fixed-case">MXRA</styled-content>5 function in cultured human proximal tubular epithelial cells and explored <styled-content style="fixed-case">MXRA</styled-content>5 expression in kidney cancer cells and kidney tissue. The fibrogenic cytokine transforming growth factorâÎ²1 (<styled-content style="fixed-case">TGF</styled-content>Î²1) upâregulated <styled-content style="fixed-case">MXRA</styled-content>5 <styled-content style="fixed-case">mRNA</styled-content> and protein expression. <styled-content style="fixed-case">TGF</styled-content>Î²1âinduced <styled-content style="fixed-case">MXRA</styled-content>5 upâregulation was prevented by either interference with <styled-content style="fixed-case">TGF</styled-content>Î²1 activation of the <styled-content style="fixed-case">TGF</styled-content>Î² receptor 1 (<styled-content style="fixed-case">TGFBR</styled-content>1, <styled-content style="fixed-case">ALK</styled-content>5) or by the vitamin D receptor agonist paricalcitol. By contrast, the proâinflammatory cytokine <styled-content style="fixed-case">TWEAK</styled-content> did not modulate <styled-content style="fixed-case">MXRA</styled-content>5 expression. <styled-content style="fixed-case">MXRA</styled-content>5 si<styled-content style="fixed-case">RNA</styled-content>âinduced downâregulation of constitutive <styled-content style="fixed-case">MXRA</styled-content>5 expression resulted in higher <styled-content style="fixed-case">TWEAK</styled-content>âinduced expression of chemokines. In addition, <styled-content style="fixed-case">MXRA</styled-content>5 downâregulation resulted in a magnified expression of genes encoding extracellular matrix proteins in response to <styled-content style="fixed-case">TGF</styled-content>Î²1. Furthermore, in clear cell renal cancer, von HippelâLindau (VHL) regulated <styled-content style="fixed-case">MXRA</styled-content>5 expression. In conclusion, <styled-content style="fixed-case">MXRA</styled-content>5 is a <styled-content style="fixed-case">TGF</styled-content>Î²1â and <styled-content style="fixed-case">VHL</styled-content>âregulated protein and, for the first time, we identify <styled-content style="fixed-case">MXRA</styled-content>5 functions as an antiâinflammatory and antiâfibrotic molecule. This information may yield clues to design novel therapeutic strategies in diseases characterized by inflammation and fibrosis.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="jcmm12953-kwd-0001">chronic kidney disease</kwd>
        <kwd id="jcmm12953-kwd-0002">fibrosis</kwd>
        <kwd id="jcmm12953-kwd-0003">kidney</kwd>
        <kwd id="jcmm12953-kwd-0004">inflammation</kwd>
        <kwd id="jcmm12953-kwd-0005">polycystic kidney disease</kwd>
        <kwd id="jcmm12953-kwd-0006">perlecan</kwd>
        <kwd id="jcmm12953-kwd-0007">adlican</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Instituto de Salud Carlos III</funding-source>
          <award-id>ISCIII RETIC REDINREN RD12/0021</award-id>
          <award-id>PI13/00047</award-id>
          <award-id>PI15/00298</award-id>
          <award-id>PIE13/00051</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Comunidad de Madrid</funding-source>
          <award-id>CIFRA S2010/BMDâ2378</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Sociedad EspaÃ±ola de NefrologÃ­a</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Programa IntensificaciÃ³n Actividad Investigadora</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>ISCIII Joan Rodes</funding-source>
          <award-id>JR14/00028</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Miguel Servet</funding-source>
          <award-id>MS12/03262</award-id>
          <award-id>MS14/00133</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Biobanco IISâFJD</funding-source>
          <award-id>PT13/0010/0012</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="8"/>
        <table-count count="2"/>
        <page-count count="11"/>
        <word-count count="6067"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>jcmm12953</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January 2017</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.0 mode:remove_FC converted:27.12.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="jcmm12953-sec-0001">
      <title>Introduction</title>
      <p>Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for more than 3 months, with implications for health <xref rid="jcmm12953-bib-0001" ref-type="ref">1</xref>. Indeed, CKD is among the fastest growing causes of death worldwide and is a major cause of disability [<xref rid="jcmm12953-bib-0002" ref-type="ref">2</xref>, <xref rid="jcmm12953-bib-0003" ref-type="ref">3</xref>]. Mortality results both from accelerated cardiovascular disease and from progression to endâstage renal disease (ESRD). ESRD patients require lifelong dialysis or kidney transplantation and have a mortality which is 10â to 100âfold higher than the general population <xref rid="jcmm12953-bib-0004" ref-type="ref">4</xref>. Renal inflammation and fibrosis are key pathological processes involved in the progression of CKD to ESRD. Current therapy for CKD is unsatisfactory and has failed to prevent the increase in CKDâassociated mortality. Antiâproteinuric agents targeting the reninâangiotensin system have been the backbone of kidney disease therapy for almost 30 years <xref rid="jcmm12953-bib-0005" ref-type="ref">5</xref>. However, as exemplified by diabetic nephropathy, the most common cause of ESRD worldwide, promising new drugs usually fail key phase 2 or phase 3 trials <xref rid="jcmm12953-bib-0006" ref-type="ref">6</xref>. Thus, an improved understanding of the pathogenesis of CKD and, specifically, of the molecules governing the transition to chronicity is needed in order to design novel therapeutic approaches to CKD <xref rid="jcmm12953-bib-0007" ref-type="ref">7</xref>.</p>
      <p>Inflammation is a key promoter of CKD progression, eventually leading to renal fibrosis. Renal fibrosis arises from imbalances in extracellular matrix (ECM) homoeostasis, leading to ECM accumulation. Renal fibrosis is the strongest histological predictor of CKD progression, regardless the cause of the primary disease <xref rid="jcmm12953-bib-0008" ref-type="ref">8</xref>. Among the multiple factors contributing to kidney inflammation and fibrosis, agents targeting the inflammatory cytokine TWEAK and the fibrogenic protein TGFÎ²1 have reached the clinical trial stage, albeit not yet successfully [<xref rid="jcmm12953-bib-0009" ref-type="ref">9</xref>, <xref rid="jcmm12953-bib-0010" ref-type="ref">10</xref>]. TWEAK activation of Fn14 promotes podocyte injury <xref rid="jcmm12953-bib-0011" ref-type="ref">11</xref>, tubulointerstitial inflammation <xref rid="jcmm12953-bib-0012" ref-type="ref">12</xref> and interstitial fibrosis <xref rid="jcmm12953-bib-0013" ref-type="ref">13</xref>, while TGFÎ²1 promotes fibrosis and dampens inflammation, promoting the scarring process as resolution of inflammation.</p>
      <p>Matrix remodellingâassociated protein 5 (MXRA5), also known as adhesion protein with leucineârich repeats and immunoglobulin domains related to perlecan (Adlican), is a protein of unknown function belonging to the MXRA gene family. The MXRA5 gene encodes a protein of a predicted molecular weight of 312 kDa. The MXRA family comprises three genes (MXRA5, MXRA7 and MXRA8) and is thought to participate in cell adhesion and matrix remodelling <xref rid="jcmm12953-bib-0014" ref-type="ref">14</xref>. MXRA5 is found in primates, marsupials, some mammals, birds and fishes, but not in mouse or rat. MXRA5 mRNA is upâregulated in human chronic ischaemic myocardium, together with other genes promoting ECM remodelling <xref rid="jcmm12953-bib-0015" ref-type="ref">15</xref> and in fibroblast primary cultures from centenarians <xref rid="jcmm12953-bib-0016" ref-type="ref">16</xref>. Although MXRA5 functions are not well known, these data point to a potential role in tissue injury and fibrosis. The kidney is among the highest MXRA5 expressing organs (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human%26q=MXRA5">http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human%26q=MXRA5</ext-link>; accessed May 15, 2016). Thus, we hypothesized that MXRA5 may play a role in kidney inflammation or fibrosis and we now report on the factors regulating MXRA5 expression in kidney tubular cells and, for the first time, on MXRA5 function.</p>
    </sec>
    <sec id="jcmm12953-sec-0002">
      <title>Materials and methods</title>
      <sec id="jcmm12953-sec-0003">
        <title>Ethics</title>
        <p>The IISâFundaciÃ³n JimÃ©nez DÃ­az Biobank is part of the ISCIII Network of Biobanks. The biobank and biobank consent forms have been approved by the Ethics Committee of the IISâFundaciÃ³n JimÃ©nez DÃ­az and patients who donated samples signed an informed consent form. The current project was also approved by the Ethics Committee of the IISâFundaciÃ³n JimÃ©nez DÃ­az and conforms to the Declaration of Helsinki and current Spanish legislation.</p>
      </sec>
      <sec id="jcmm12953-sec-0004">
        <title>Cells and reagents</title>
        <p>HKâ2 human proximal tubular epithelial cells (ATCC, Rockville, MD, USA) were grown on RPMI 1640 (Life Technologies, Grand Island, NY, USA) with 10% heatâinactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 100 Î¼g/ml streptomycin, 5 Î¼g/ml insulin, 5 Î¼g/ml transferrin, 5 ng/ml sodium selenite and 5 ng/ml hydrocortisone in 5% carbon dioxide at 37Â°C <xref rid="jcmm12953-bib-0017" ref-type="ref">17</xref>. VHLâdefective clear cell renal carcinoma cells (VHLâ/â ccRCC) and VHL+/+ ccRCC cells have been previously described <xref rid="jcmm12953-bib-0018" ref-type="ref">18</xref>. For experiments, cells were rested in serumâfree media 24 hr prior to the addition of stimuli and throughout the experiment. Five hundred thousand cells were seeded in 60 mm diameter wells for RNA extraction, Western blot or flow cytometry experiments. Cells were treated with 100 ng/ml TWEAK (Millipore, Watford, UK), 1 ng/ml TGFÎ²1 (Peprotech, London, UK), 100 nmol/l paricalcitol (Abbot, Chicago, Illinois), 100 Î¼mol/l TGFÎ²1 receptor 1 (ALK5) inhibitor (SB431542; SigmaâAldrich, Sigma, St. Louis, MO) or 1 ng/ml neutralizing antiâTGFÎ²1 antibody (ab100NA; R&amp;D Systems, Minneapolis, MN), based on prior doseâresponses studies from our lab.</p>
      </sec>
      <sec id="jcmm12953-sec-0005">
        <title>Transfection of small interfering RNA</title>
        <p>Cells were grown in sixâwell plates (Costar, Cambridge, MA, USA) and transfected with a mixture of 30 nmol/ml MXRA5 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), OptiâMEM I Reduced Serum Medium and Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, Life technologies, Paisley, UK). After 18 hr, cells were washed and cultured for 48 h in complete medium and serumâdepleted for 24 hr before stimulation. A scrambled siRNA (Ambion, Applied Biosystems, Foster City, CA, USA) was used as control.</p>
      </sec>
      <sec id="jcmm12953-sec-0006">
        <title>RNA extraction and realâtime polymerase chain reaction</title>
        <p>Total RNA was extracted from cells by the TRIâReagent method (SigmaâAldrich) and 1 Î¼g RNA was reverse transcribed with High Capacity cDNA Archive Kit (Applied Biosystems). Preâdeveloped primer and probe assays for MXRA5, GAPDH, MCPâ1, RANTES, CXCL16, Fibronectin, Type IV Collagen and 18S were from Applied (Applied Biosystems). Quantitative PCR was performed by 7500 RealâTime PCR System with the Prism 7000 System SDS Software (Applied Biosystems) and RNA expression of different genes was corrected for GAPDH or 18S <xref rid="jcmm12953-bib-0012" ref-type="ref">12</xref>.</p>
      </sec>
      <sec id="jcmm12953-sec-0007">
        <title>Western blot</title>
        <p>Cell samples were homogenized in lysis buffer (50 mM TrisâHCl, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2% Triton Xâ100, 0.3% NPâ40, 0.1 mM PMSF and 1 Î¼g/ml pepstatin A) and then separated by 15% SDSâPAGE under reducing conditions. After electrophoresis, samples were transferred to PVDF membranes (Millipore), blocked with 5% BSA in PBS/0.5% v/v Tween 20 for 1 hr, washed with PBS/Tween, and incubated with goat polyclonal antiâMXRA5 (1:500 in 1% BSA PBS/Tween; Santa Cruz Biotechnology). Blots were washed with PBS/Tween and incubated with appropriate horseradish peroxidaseâconjugated secondary antibody (1:2000, Santa Cruz Biotechnology). After washing with PBS/Tween, blots were developed with the chemiluminescence method (ECL) (Amersham). Blots were then probed with mouse monoclonal antiâÎ±âtubulin antibody (1:10,000; SigmaâAldrich) and levels of expression were corrected for minor differences in loading <xref rid="jcmm12953-bib-0019" ref-type="ref">19</xref>.</p>
      </sec>
      <sec id="jcmm12953-sec-0008">
        <title>Immunohistochemistry</title>
        <p>Immunohistochemistry was carried out in paraffinâembedded human kidney, fixed in 4% buffered formalin. The primary antibody was goat polyclonal antiâMXRA5 (1:100; Santa Cruz biotechnology). Briefly, 5âÎ¼mâthick renal sections were adhered to polylysineâcoated glass slides and fixed overnight at 56Â°C. After deparaffinization through xylene, alcohol and distilled water, endogenous peroxidase was blocked by 3% H<sub>2</sub>O<sub>2</sub> for 30 min. Sections were microwaved in 0.1 mM citrate buffer pH 6.0 for 20 min., and transferred to distilled water. After rinsing in phosphateâbuffered saline (PBS), sections were incubated with 1:10 normal donkey serum in PBS/4% BSA and then incubated overnight at 4Â°C with goat antiâhuman MXRA5. Next, they were incubated with biotinylated rabbit antiâgoat antibody (1:300) in PBSâ4% BSA for 30 min. at room temperature. After three rinses in PBS, they were incubated with streptavidinâperoxidase (Dako, Denmark) 1:500 for 30 min. Colour was developed with diaminobenzidine and then counterstained with haematoxylin, dehydrated and mounted with Canadian balsam (Polysciences). Specificity was checked by omission of primary antibodies and use of nonâimmune sera.</p>
        <p>Human kidney urine and tissue was obtained from the IISâFundaciÃ³n JimÃ©nez DÃ­az Biobank. Table S1 shows a clinical characterization of patients.</p>
      </sec>
      <sec id="jcmm12953-sec-0009">
        <title>Database search</title>
        <p>The following databases were searched for MXAR5: Ensembl, ClinVar, GEO profiles (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geoprofiles/?term=MXRA5+kidney">http://www.ncbi.nlm.nih.gov/geoprofiles/?term=MXRA5+kidney</ext-link>), Kidney &amp; Urinary Pathway Knowledge Base (kupkb at <ext-link ext-link-type="uri" xlink:href="http://www.kupkb.org/">http://www.kupkb.org/</ext-link>) and nephromine (<ext-link ext-link-type="uri" xlink:href="http://www.nephromine.org/">http://www.nephromine.org/</ext-link>).</p>
      </sec>
      <sec id="jcmm12953-sec-0010">
        <title>Statistics</title>
        <p>Statistical analysis was performed with SPSS 11.0 statistical software. Results are expressed as mean Â± SEM for protein and mRNA expression experiments. Significance at the <italic>P</italic> &lt; 0.05 level was assessed by Student's <italic>t</italic>âtest for two groups of data and <sc>anova</sc> for three or more groups.</p>
      </sec>
    </sec>
    <sec id="jcmm12953-sec-0011">
      <title>Results</title>
      <sec id="jcmm12953-sec-0012">
        <title>MXRA5 is upâregulated in human kidney disease</title>
        <p>MXRA5 is an evolutionary conserved gene. Although absent from mouse and rat, MXRA5 is expressed in a wide range of human organs and especially, in the normal human kidney (Fig. <xref rid="jcmm12953-fig-0001" ref-type="fig">1</xref>). The human kidney has relatively high levels of MXRA5 mRNA as compared to other organs <xref rid="jcmm12953-bib-0020" ref-type="ref">20</xref> (Fig. <xref rid="jcmm12953-fig-0001" ref-type="fig">1</xref>B) (Table <xref rid="jcmm12953-tbl-0001" ref-type="table-wrap">1</xref>). In publicly available databases, MXRA5 was found to be upâregulated in several forms of CKD, such as focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, lupus nephritis, rapidly progressing glomerulonephritis and dysfunctional transplanted kidneys as well as in clear cell sarcoma, while there was no change in nephrosclerosis or renal cell carcinoma (Table <xref rid="jcmm12953-tbl-0002" ref-type="table-wrap">2</xref>
<bold>)</bold>. Furthermore, the kupkb database reflected the finding of MXRA5 in exosomes from normal urine in the Urinary Exosome Protein Database (<ext-link ext-link-type="uri" xlink:href="http://dir.nhlbi.nih.gov/papers/lkem/exosome/">http://dir.nhlbi.nih.gov/papers/lkem/exosome/</ext-link>). According to Nephromine, in FSGS, the nephropathy with highest MXAR5 expression, the best correlate of MXRA5 expression was the expression of the TWEAK receptor, Fn14 (correlation 0.713) (Fig. <xref rid="jcmm12953-fig-0001" ref-type="fig">1</xref>C) <xref rid="jcmm12953-bib-0021" ref-type="ref">21</xref>.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm12953-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>The <styled-content style="fixed-case">MXRA</styled-content>5 gene. <bold>(A)</bold> Gene tree representing <styled-content style="fixed-case">MXRA</styled-content>5 orthologues. The display shows the maximum likelihood phylogenetic tree representing the evolutionary history of gene. Note the existence of a human gene (Ensembl: accessed on January 25th). <bold>(B) </bold>
<styled-content style="fixed-case">MXRA</styled-content>5 gene expression in diverse human organs according to publicly accessible databases. Note high kidney <styled-content style="fixed-case">MXRA</styled-content>5 <styled-content style="fixed-case">mRNA</styled-content> levels as compared to other organs (<italic>n</italic> = 10, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> Universal <styled-content style="fixed-case">RNA</styled-content>; source: <styled-content style="fixed-case">GEO</styled-content> 17426686, 4689086). <bold>(C)</bold> Correlation between <styled-content style="fixed-case">MXRA</styled-content>5 and Fn14 (<styled-content style="fixed-case">TNFRSF</styled-content>12A) <styled-content style="fixed-case">mRNA</styled-content> expression in human focal segmental glomerulosclerosis according to publicly accessible databases. Source: Nephromine <xref rid="jcmm12953-bib-0021" ref-type="ref">21</xref>.</p>
          </caption>
          <graphic id="nlm-graphic-1" xlink:href="JCMM-21-154-g001"/>
        </fig>
        <table-wrap id="jcmm12953-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>MXRA5 expression in different human tissues</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1"/>
                <th align="center" valign="top" rowspan="1" colspan="1">
<bold>nâfold</bold>
</th>
                <th align="center" valign="top" rowspan="1" colspan="1">
<italic><bold>P</bold></italic>
<bold>âvalue</bold>
</th>
                <th align="left" valign="top" rowspan="1" colspan="1">
<bold>Reference</bold>
</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Kidney <italic>versus</italic> liver</td>
                <td align="char" char="." rowspan="1" colspan="1">1.57</td>
                <td align="char" char="." rowspan="1" colspan="1">0.009</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0044" ref-type="ref">44</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Kidney <italic>versus</italic> heart</td>
                <td align="char" char="." rowspan="1" colspan="1">1.34</td>
                <td align="char" char="." rowspan="1" colspan="1">0.033</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0044" ref-type="ref">44</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Kidney <italic>versus</italic> liver</td>
                <td align="char" char="." rowspan="1" colspan="1">3.12</td>
                <td align="char" char="." rowspan="1" colspan="1">0.001</td>
                <td align="left" rowspan="1" colspan="1">GEO: GDS1663/209596</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Kidney <italic>versus</italic> spleen</td>
                <td align="char" char="." rowspan="1" colspan="1">2.06</td>
                <td align="char" char="." rowspan="1" colspan="1">0.001</td>
                <td align="left" rowspan="1" colspan="1">GEO: GDS1663/209596</td>
              </tr>
            </tbody>
          </table>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <table-wrap id="jcmm12953-tbl-0002" xml:lang="en" orientation="portrait" position="float">
          <label>Table 2</label>
          <caption>
            <p>MXRA5 mRNA expression in human kidney disease according to publicly available transcriptomics datasets</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">
<bold>Group</bold>
</th>
                <th align="center" valign="top" rowspan="1" colspan="1">
<bold>nâfold</bold>
</th>
                <th align="center" valign="top" rowspan="1" colspan="1">
<italic><bold>P</bold></italic>
<bold>âvalue</bold>
</th>
                <th align="left" valign="top" rowspan="1" colspan="1">
<bold>Reference</bold>
</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Clear cell sarcoma of the kidney <italic>versus</italic> control</td>
                <td align="char" char="." rowspan="1" colspan="1">4.79</td>
                <td align="char" char="." rowspan="1" colspan="1">0.003</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0045" ref-type="ref">45</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Focal segmental glomerulosclerosis <italic>versus</italic> normal kidney/minimal change disease</td>
                <td align="char" char="." rowspan="1" colspan="1">4.58</td>
                <td align="char" char="." rowspan="1" colspan="1">0.001</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0021" ref-type="ref">21</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Diabetic nephropathy <italic>versus</italic> healthy living donor (glomeruli)</td>
                <td align="char" char="." rowspan="1" colspan="1">1.96</td>
                <td align="char" char="." rowspan="1" colspan="1">0.05</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0046" ref-type="ref">46</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Lupus Nephritis <italic>versus</italic> healthy living donor (tubulointerstitium)</td>
                <td align="char" char="." rowspan="1" colspan="1">1.75</td>
                <td align="char" char="." rowspan="1" colspan="1">0.043</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0047" ref-type="ref">47</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Diabetic nephropathy <italic>versus</italic> minimal change disease</td>
                <td align="char" char="." rowspan="1" colspan="1">1.53</td>
                <td align="char" char="." rowspan="1" colspan="1">0.029</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0048" ref-type="ref">48</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Rapidly progressive glomerulonephritis <italic>versus</italic> healthy living donor/minimal change disease (glomeruli)</td>
                <td align="char" char="." rowspan="1" colspan="1">1.48</td>
                <td align="char" char="." rowspan="1" colspan="1">0.018</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0049" ref-type="ref">49</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Diabetic nephropathy <italic>versus</italic> healthy living donor/minimal change disease</td>
                <td align="char" char="." rowspan="1" colspan="1">1.47</td>
                <td align="char" char="." rowspan="1" colspan="1">0.008</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0049" ref-type="ref">49</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Renal dysfunction <italic>versus</italic> healthy living donor</td>
                <td align="char" char="." rowspan="1" colspan="1">1.24</td>
                <td align="char" char="." rowspan="1" colspan="1">0.003</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="jcmm12953-bib-0050" ref-type="ref">50</xref>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="jcmm12953-note-0002">
              <p>No significant differences were found for nephrosclerosis: glomeruli <italic>versus</italic> healthy glomeruli from tumourâfree nephrectomy specimens <xref rid="jcmm12953-bib-0051" ref-type="ref">51</xref> or for renal cell carcinoma <italic>versus</italic> adjacent nonâtumour tissue <xref rid="jcmm12953-bib-0052" ref-type="ref">52</xref>.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <p>Consistent with transcriptomics databases, proteins immuneâreactive for antiâMXRA5 antibody were found both in the supernatant and sediment of centrifuged unconcentrated urine in CKD patients (samples 1â3; Table S1), but not in healthy controls (samples 4 and 5; Table S1) (Fig. <xref rid="jcmm12953-fig-0002" ref-type="fig">2</xref>A and B). Furthermore, MXRA5 mRNA expression was increased in cysts from autosomal dominant polycystic kidney disease (ADPKD) patients (Fig. <xref rid="jcmm12953-fig-0002" ref-type="fig">2</xref>C) and expression was localized to cyst lining tubular cells by immunohistochemistry (Fig. <xref rid="jcmm12953-fig-0002" ref-type="fig">2</xref>D). Immunohistochemistry also localized MXRA5 staining to tubular cells in nonâADPKD kidney fibrosis (Fig. <xref rid="jcmm12953-fig-0002" ref-type="fig">2</xref>E, corresponding to samples 16â18; Table S1).</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm12953-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>
<styled-content style="fixed-case">MXRA</styled-content>5 is present in <styled-content style="fixed-case">CKD</styled-content> patients. (<bold>A</bold>) Urine supernatant. (<bold>B</bold>) Urine sediment. Western blot shows bands recognized by antiâ<styled-content style="fixed-case">MXRA</styled-content>5 antibody in urine of <styled-content style="fixed-case">CKD</styled-content> patients but not in healthy controls (<italic>N</italic> = 2 healthy controls and 3 <styled-content style="fixed-case">CKD</styled-content> patients). (<bold>C</bold>) <styled-content style="fixed-case">MXRA</styled-content>5 <styled-content style="fixed-case">mRNA</styled-content> expression in <styled-content style="fixed-case">ADPKD</styled-content> cysts or normal kidneys assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3 controls and 6 <styled-content style="fixed-case">ADPKD</styled-content> patients, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> control). (<bold>D</bold>) <styled-content style="fixed-case">MXRA</styled-content>5 immunohistochemistry in <styled-content style="fixed-case">ADPKD</styled-content> cysts or normal kidneys (<italic>N</italic> = 6 controls and 6 <styled-content style="fixed-case">ADPKD</styled-content> patients). Representative image. (<bold>E</bold>) <styled-content style="fixed-case">MXRA</styled-content>5 immunohistochemistry in renal fibrosis and control kidney (<italic>N</italic> = 2 controls and 1 fibrotic, nonâ<styled-content style="fixed-case">ADPKD</styled-content> kidney).</p>
          </caption>
          <graphic id="nlm-graphic-3" xlink:href="JCMM-21-154-g002"/>
        </fig>
      </sec>
      <sec id="jcmm12953-sec-0013">
        <title>TGFÎ²1 and paricalcitol regulate MXRA5 expression in cultured human tubular cells</title>
        <p>After observing an upâregulation of MXAR5 expression in human nephropathies characterized by kidney inflammation and fibrosis, we explored the potential regulation of MXRA5 expression by a representative fibrogenic cytokine TGFÎ²1 and a representative proâinflammatory cytokine, TWEAK. Therapies targeting TWEAK and TGFÎ²1 are under clinical development. Despite the good correlation between MXRA5 and Fn14 expression in FSGS, TWEAK did not modulate MXRA5 mRNA levels in tubular cells (Fig. S1). MXRA5 being an ECM protein, we next tested its regulation by TGFÎ²1. TGFÎ²1 doseâdependently upâregulated MXRA5 mRNA expression (Fig. <xref rid="jcmm12953-fig-0003" ref-type="fig">3</xref>A). The concentration of 1 ng/ml TGFÎ²1 was chosen for further studies. Stimulation of tubular cells with 1 ng/ml TGFâÎ²1 upâregulated MXRA5 protein levels in whole cells in a timeâdependent manner (Fig. <xref rid="jcmm12953-fig-0003" ref-type="fig">3</xref>B) TGFÎ²1âinduced MXRA5 upâregulation was prevented by the TGFÎ²1 receptor 1 (ALK5) inhibitor SB431542 (Fig. <xref rid="jcmm12953-fig-0003" ref-type="fig">3</xref>C and D) and by the neutralizing antiâTGFÎ²1 antibody ab100NA (Fig. <xref rid="jcmm12953-fig-0003" ref-type="fig">3</xref>E and F). Vitamin D has been shown to regulate kidney fibrosis. The vitamin D receptor activator paricalcitol also inhibited the increase in MXRA5 mRNA (Fig. <xref rid="jcmm12953-fig-0004" ref-type="fig">4</xref>A) and protein expression (Fig. <xref rid="jcmm12953-fig-0004" ref-type="fig">4</xref>B) induced by TGFÎ²1.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm12953-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>
<styled-content style="fixed-case">TGF</styled-content>Î²1 increases <styled-content style="fixed-case">MXRA</styled-content>5 in cultured proximal tubular cells. (<bold>A</bold>) Human proximal tubular cells were exposed to 0.1, 1 and 10 ng/ml <styled-content style="fixed-case">TGF</styled-content>Î²1 for 3 and 6 hr and <styled-content style="fixed-case">MXRA</styled-content>5 <styled-content style="fixed-case">mRNA</styled-content> expression was assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> control, #<italic>P</italic> &lt; 0.01 <italic>versus</italic> control). (<bold>B</bold>) Cells were exposed to 1 ng/ml <styled-content style="fixed-case">TGF</styled-content>Î²1 for 3, 6 and 24 hr and <styled-content style="fixed-case">MXRA</styled-content>5 protein expression was assessed by Western blot. Tubulin was used as loading control (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.025 <italic>versus</italic> control, #<italic>P</italic> &lt; 0.05 <italic>versus</italic> control). (<bold>C</bold>) Cells were preâtreated with 10<sup>â5</sup> M <styled-content style="fixed-case">TGF</styled-content>Î²1 receptor 1 inhibitor <styled-content style="fixed-case">SB</styled-content>431542 for 1 hr and then exposed to 1 ng/ml <styled-content style="fixed-case">TGF</styled-content>Î²1 for 3 and 6 hr, <styled-content style="fixed-case">MXRA</styled-content>5 <styled-content style="fixed-case">mRNA</styled-content> expression was assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> control, #<italic>P</italic> &lt; 0.006 <italic>versus</italic> control). (<bold>D</bold>) Cells were preâtreated with 10<sup>â5</sup> M <styled-content style="fixed-case">SB</styled-content>431542 for 1 hr and then exposed to 1 ng/ml <styled-content style="fixed-case">TGF</styled-content>Î²1 for 6 hr, <styled-content style="fixed-case">MXRA</styled-content>5 protein levels were assessed by Western blot (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.005 <italic>versus</italic> control). (<bold>E</bold>) Cells were preâtreated with 1 ng/ml neutralizing antiâ<styled-content style="fixed-case">TGF</styled-content>Î²1 antibody ab100<styled-content style="fixed-case">NA</styled-content> for 1 hr and then exposed to 1 ng/ml <styled-content style="fixed-case">TGF</styled-content>Î²1 for 3 and 6 hr, <styled-content style="fixed-case">MXRA</styled-content>5 <styled-content style="fixed-case">mRNA</styled-content> expression was assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> control). (<bold>F</bold>) Cells were preâtreated with 1 ng/ml neutralizing antiâ<styled-content style="fixed-case">TGF</styled-content>Î²1 antibody ab100<styled-content style="fixed-case">NA</styled-content> for 1 hr and then exposed to 1 ng/ml <styled-content style="fixed-case">TGF</styled-content>Î²1 for 6 hr, <styled-content style="fixed-case">MXRA</styled-content>5 protein levels were assessed by Western blot (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.005 <italic>versus</italic> control, #<italic>P</italic> &lt; 0.018 <italic>versus</italic> control).</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="JCMM-21-154-g003"/>
        </fig>
        <fig fig-type="Figure" xml:lang="en" id="jcmm12953-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Paricalcitol prevents <styled-content style="fixed-case">TGF</styled-content>Î²1âinduced <styled-content style="fixed-case">MXRA</styled-content>5 upâregulation. Cells were preâtreated with 1 Î¼g/ml paricalcitol for 90 min. and then exposed to 1 ng/ml <styled-content style="fixed-case">TGF</styled-content>Î²1 for 6 hr. (<bold>A</bold>) <styled-content style="fixed-case">MXRA</styled-content>5 <styled-content style="fixed-case">mRNA</styled-content> expression was assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> control, #<italic>P</italic> &lt; 0.018 <italic>versus</italic> control). (<bold>B</bold>) <styled-content style="fixed-case">MXRA</styled-content>5 protein expression was assessed by Western blot (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.02 <italic>versus</italic> control, #<italic>P</italic> &lt; 0.05 <italic>versus</italic> control).</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="JCMM-21-154-g004"/>
        </fig>
      </sec>
      <sec id="jcmm12953-sec-0014">
        <title>MXRA5 has antiâinflammatory and antiâfibrotic properties in cultured tubular cells</title>
        <p>MXRA5 was knocked down by means of specific MXRA5 siRNA (Fig. <xref rid="jcmm12953-fig-0005" ref-type="fig">5</xref>A and B). Downâregulation of MXRA5 did not alter the morphological appearance of cells for up to 72 hr (Fig. <xref rid="jcmm12953-fig-0005" ref-type="fig">5</xref>C), and changes in cell cycle or cell death were not observed upon MXRA5 downâregulation (Fig. <xref rid="jcmm12953-fig-0005" ref-type="fig">5</xref>D).</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm12953-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <p>
<styled-content style="fixed-case">MXRA</styled-content>5 targeting has no effect on cell viability or proliferation. <styled-content style="fixed-case">MXRA</styled-content>5 was successfully knocked down by means of a specific si<styled-content style="fixed-case">RNA</styled-content>. (<bold>A</bold>) <styled-content style="fixed-case">MXRA</styled-content>5 protein expression was assessed by Western blot (<bold>B</bold>) and <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (*<italic>P</italic> &lt; 0.001 <italic>versus</italic> control). (<bold>C</bold>) No morphological changes were observed in <styled-content style="fixed-case">MXRA</styled-content>5 knocked down cells. Contrast phase microscopy. (<bold>D</bold>) No changes in cell death or proliferation were observed in <styled-content style="fixed-case">MXRA</styled-content>5âsilenced cells. <styled-content style="fixed-case">DNA</styled-content> was stained with propidium iodide in permeabilized cells and <styled-content style="fixed-case">DNA</styled-content> content quantified by flow cytometry.</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="JCMM-21-154-g005"/>
        </fig>
        <p>As previously described, TWEAK elicited proâinflammatory responses in tubular cells [<xref rid="jcmm12953-bib-0012" ref-type="ref">12</xref>, <xref rid="jcmm12953-bib-0022" ref-type="ref">22</xref>]. Downâregulation of MXRA5 resulted in increased expression of chemokine mRNA in response to TWEAK stimulation (Fig. <xref rid="jcmm12953-fig-0006" ref-type="fig">6</xref>), as well as in increased MCPâ1 protein levels in cell supernatants (Fig. <xref rid="jcmm12953-fig-0006" ref-type="fig">6</xref>B), suggesting that endogenous constitutive MXRA5 may play an antiâinflammatory role. TGFÎ²1 is a key fibrogenic cytokine in tubular cells and kidney injury <xref rid="jcmm12953-bib-0023" ref-type="ref">23</xref>. MXRA5 downâregulation resulted in increased expression of genes encoding the ECM proteins fibronectin and type IV collagen in response to TGFÎ²1 stimulation (Fig. <xref rid="jcmm12953-fig-0007" ref-type="fig">7</xref>), suggesting that TGFÎ²1âinduced MXRA5 expression contributes to limit the fibrogenic response of tubular cells. These results suggest that constitutive or inducible MXRA5 has antiâinflammatory and antiâfibrotic properties.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm12953-fig-0006" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Endogenous constitutive <styled-content style="fixed-case">MXRA</styled-content>5 has an antiâinflammatory role in cultured proximal tubular cells. <styled-content style="fixed-case">MXRA</styled-content>5 was knocked down and then cells were treated with 100 ng/ml <styled-content style="fixed-case">TWEAK</styled-content> for 3 hr. <styled-content style="fixed-case">TWEAK</styled-content> did not modify <styled-content style="fixed-case">MXRA</styled-content>5 expression (supplemental figure). (<bold>A</bold>) <styled-content style="fixed-case">MCP</styled-content>1 <styled-content style="fixed-case">mRNA</styled-content> expression assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.002 <italic>versus</italic> control). (<bold>B</bold>) <styled-content style="fixed-case">MCP</styled-content>1 secretion assessed by <styled-content style="fixed-case">ELISA</styled-content> in cell supernatants (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.025). (<bold>C</bold>) Rantes <styled-content style="fixed-case">mRNA</styled-content> expression assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> control). (<bold>D</bold>) Cxcl16 <styled-content style="fixed-case">mRNA</styled-content> expression assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> control).</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="JCMM-21-154-g006"/>
        </fig>
        <fig fig-type="Figure" xml:lang="en" id="jcmm12953-fig-0007" orientation="portrait" position="float">
          <label>Figure 7</label>
          <caption>
            <p>
<styled-content style="fixed-case">MXRA</styled-content>5 has an antiâfibrotic role in cultured proximal tubular cells. <styled-content style="fixed-case">MXRA</styled-content>5 was knocked down and then cells were treated with 1 ng/ml <styled-content style="fixed-case">TGF</styled-content>Î²1 for 6 hr. (<bold>A</bold>) Fibronectin <styled-content style="fixed-case">mRNA</styled-content> expression assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.001 <italic>versus</italic> control, #<italic>P</italic> &lt; 0.005 <italic>versus</italic> control). (<bold>B</bold>) Type <styled-content style="fixed-case">IV</styled-content> collagen <styled-content style="fixed-case">mRNA</styled-content> expression assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3, *<italic>P</italic> &lt; 0.002 <italic>versus</italic> control).</p>
          </caption>
          <graphic id="nlm-graphic-13" xlink:href="JCMM-21-154-g007"/>
        </fig>
      </sec>
      <sec id="jcmm12953-sec-0015">
        <title>MXRA5 in kidney cancer</title>
        <p>As MXRA5 is overexpressed in ovarian, lung and colorectal cancer <xref rid="jcmm12953-bib-0024" ref-type="ref">24</xref>, <xref rid="jcmm12953-bib-0025" ref-type="ref">25</xref>, <xref rid="jcmm12953-bib-0026" ref-type="ref">26</xref>, we studied MXRA5 expression in VHLâdefective ccRCC cell line (VHL<sup>â/â</sup>). MXRA5 mRNA expression was assessed in untreated HK2 cells and VHL<sup>â/â</sup> cells, as well as VHLâexpressing ccRCC cells (VHL<sup>+/+</sup>) (Fig. <xref rid="jcmm12953-fig-0008" ref-type="fig">8</xref>A). No MXRA5 mRNA expression was observed in VHL<sup>â/â</sup> cells, suggesting a relationship between MXRA5 and tumourigenesis. We then studied MXRA5 expression in renal biopsies from renal carcinoma patients. We observed a direct relationship between VHL and MXRA5 transcriptional expression (Fig. <xref rid="jcmm12953-fig-0008" ref-type="fig">8</xref>B). Thus, those patients with low VHL expression showed low MXRA5 expression, as observed for cultured ccRCC.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm12953-fig-0008" orientation="portrait" position="float">
          <label>Figure 8</label>
          <caption>
            <p>
<styled-content style="fixed-case">MXRA</styled-content>5 in cancer. (<bold>A</bold>) Human proximal tubular cells and <styled-content style="fixed-case">VHL</styled-content>
<sup>â/â</sup> and <styled-content style="fixed-case">VHL</styled-content>
<sup>+/+</sup> clear cell carcinoma cells were serumâdepleted and collected at 1, 3, 6 and 24 hr. <styled-content style="fixed-case">MXRA</styled-content>5 <styled-content style="fixed-case">mRNA</styled-content> expression was assessed by <styled-content style="fixed-case">RT</styled-content>â<styled-content style="fixed-case">qPCR</styled-content> (<italic>N</italic> = 3). (<bold>B</bold>) <styled-content style="fixed-case">MXRA</styled-content>5 and <styled-content style="fixed-case">VHL mRNA</styled-content> expression assessed in biopsies from renal carcinoma tissue (<italic>N</italic> = 10) and healthy kidney tissue (<italic>n</italic> = 9) from the same kidney (*<italic>P</italic> &lt; 0.05).</p>
          </caption>
          <graphic id="nlm-graphic-15" xlink:href="JCMM-21-154-g008"/>
        </fig>
      </sec>
    </sec>
    <sec id="jcmm12953-sec-0016">
      <title>Discussion</title>
      <p>The main finding of our study is that MXRA5 is an antiâinflammatory and antiâfibrotic molecule upâregulated by the fibrogenic cytokine TGFÎ²1 in human proximal tubular cells. This knowledge may be used to develop novel therapies for CKD.</p>
      <p>CKD is characterized by inflammation and accumulation of extracellular matrix and TWEAK and TGFâÎ²1 were chosen as representative proâinflammatory and fibrogenic cytokines respectively. Tubular cells are key cells in tubulointerstitial inflammation. In response to an adverse microenvironment, tubular cells are activated to express chemotactic, proâinflammatory and proâfibrotic molecules, including cytokines such as TNF, Fas ligand, TRAIL and TWEAK and chemokines such as MCPâ1, RANTES and CXCl16 that decisively contribute to recruit inflammatory cells and to promote kidney injury [<xref rid="jcmm12953-bib-0012" ref-type="ref">12</xref>, <xref rid="jcmm12953-bib-0022" ref-type="ref">22</xref>, <xref rid="jcmm12953-bib-0027" ref-type="ref">27</xref>, <xref rid="jcmm12953-bib-0028" ref-type="ref">28</xref>]. In this regard, tubulointerstitial damage correlates better with outcome of renal function than glomerular injury scores, even for primary glomerulonephritis <xref rid="jcmm12953-bib-0029" ref-type="ref">29</xref>. Indeed, tubulointerstitial fibrosis is considered an important predictor of renal survival <xref rid="jcmm12953-bib-0030" ref-type="ref">30</xref> and TGFÎ²1 is a key proâfibrotic cytokine that contributes to renal fibrosis <xref rid="jcmm12953-bib-0031" ref-type="ref">31</xref>, <xref rid="jcmm12953-bib-0032" ref-type="ref">32</xref>, <xref rid="jcmm12953-bib-0033" ref-type="ref">33</xref>, while TWEAK is a key proâinflammatory cytokine which promotes glomerular and tubulointerstitial inflammation and fibrosis <xref rid="jcmm12953-bib-0012" ref-type="ref">12</xref>. Upâregulation of TGFâÎ²1 is a universal finding in CKD, both in animal models and in humans. Inhibition of TGFÎ²1 by multiple strategies suppresses renal fibrotic lesions and prevents progressive loss of kidney function <xref rid="jcmm12953-bib-0034" ref-type="ref">34</xref>. Interestingly, TGFÎ²1 also has antiâinflammatory actions. Indeed, TGFâÎ²1 KO mice display a systemic inflammatory disease, causing, among others, kidney inflammation <xref rid="jcmm12953-bib-0035" ref-type="ref">35</xref>. We have now observed that TGFÎ²1, but not the inflammatory cytokine TWEAK, upâregulated MXRA5 expression in tubular cells through the activation of the TGFR1 receptor. This suggests that MXRA5 might mediate some TGFÎ²1 actions. In this regard siRNA targeting of MXRA5 led to a striking increase in the proâinflammatory response to TWEAK. Thus, MXRA5, as TGFÎ²1, behaves as an antiâinflammatory molecule in tubular cells. By contrast, MXRA5 targeting magnified TGFÎ²1âinduced expression of ECM genes, suggesting that MXRA5 may also limit some TGFÎ²1âelicited responses, such as fibrosis. Overall, the dual antiâinflammatory and antiâfibrotic activity of MXRA5 suggests that this is a molecule of potential therapeutic interest and that MXRA5 upâregulation in CKD may be an adaptive response that breaks inflammation and fibrosis. In this regard, characterization of the MXRA5 receptor and generation of agonistic peptides may provide a new avenue for research in kidney disease. However, the fact that mice and rats do not express MXRA5 will complicate the development of preclinical models to address its <italic>in vivo</italic> function in kidney disease. The observation that the VDR activator paricalcitol prevents MXRA5 upâregulation in response to TGFÎ²1 is especially interesting. Thus, paricalcitol has antiâinflammatory and antiâfibrotic properties that may compensate for the loss of the antiâinflammatory and antiâfibrotic action of MXRA5 [<xref rid="jcmm12953-bib-0036" ref-type="ref">36</xref>, <xref rid="jcmm12953-bib-0037" ref-type="ref">37</xref>]. Thus, paricalcitol directly decreased the expression of cytokines and extracellular matrix and moderated Wnt/Î²âcatenin signalling and NFâÎºB and Snail activation in cultured renal cells <xref rid="jcmm12953-bib-0036" ref-type="ref">36</xref>, <xref rid="jcmm12953-bib-0037" ref-type="ref">37</xref>, <xref rid="jcmm12953-bib-0038" ref-type="ref">38</xref>, <xref rid="jcmm12953-bib-0039" ref-type="ref">39</xref>, <xref rid="jcmm12953-bib-0040" ref-type="ref">40</xref>. While nephroprotective actions of VDR activation have been observed in numerous rat and mice models, human confirmation is lacking <xref rid="jcmm12953-bib-0041" ref-type="ref">41</xref>. Among the potential explanations for this discrepancy, we should now add the lack of MXRA5 in rats and mice used as models of kidney disease, while this potentially nephroprotective molecule is present in humans and downâregulated by VDR activators. Thus, we speculate that the coexistence of nephroprotective and nonânephroprotective actions of paricalcitol may be one of the contributing factors to the clinical failure of paricalcitol in kidney disease.</p>
      <p>Urine contained antiâMXRA5 immunoreactive peptides that may correspond to proteolytic fragments of MXRA5. Their presence in urine from CKD patients may point to a potential role as a biomarker. However, given the diverse sizes of the bands observed, this result should be considered preliminary. In this regard, increased tubular cell expression of MXRA5 was observed in human CKD tissue. The finding of MXRA5 in normal urine exosomes <xref rid="jcmm12953-bib-0042" ref-type="ref">42</xref> may account for its presence in urine and might even contribute to its biological activity.</p>
      <p>The present findings may also be relevant for cancer. MXRA5 was found overexpressed in ovarian cancer compared with normal ovaries and it was involved in tumour angiogenesis <xref rid="jcmm12953-bib-0024" ref-type="ref">24</xref>. It is also among the most frequently mutated genes in nonâsmall cell lung carcinomas <xref rid="jcmm12953-bib-0025" ref-type="ref">25</xref>. MXRA5 was proposed as a novel biomarker in colorectal cancer <xref rid="jcmm12953-bib-0026" ref-type="ref">26</xref>, as it was overexpressed in colorectal cancer tissue compared with their corresponding normal tissue [<xref rid="jcmm12953-bib-0026" ref-type="ref">26</xref>, <xref rid="jcmm12953-bib-0043" ref-type="ref">43</xref>]. Our results further show that VHL may be a driver of MXRA5 expression in cancer cells.</p>
      <p>In conclusion, MXRA5 is a molecule involved in the regulation of important biological processes, such as inflammation and fibrosis, during kidney disease. Additional studies will be required to determine the clinical relevance of MXRA5 as a biomarker in renal disease as well as to better characterize the molecular determinants of MXRA5 action, including the search for receptors.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data">
        <caption>
          <p>
<bold>Figure S1</bold> TWEAK does not modulate MXRA5 expression.</p>
        </caption>
        <media xlink:href="JCMM-21-154-s001.tif">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>
<bold>Table S1</bold> Clinical characteristics of patients</p>
        </caption>
        <media xlink:href="JCMM-21-154-s002.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="jcmm12953-sec-0017">
      <title>Acknowledgements</title>
      <p>This work was supported by grants from the Instituto de Salud Carlos III (FEDER funds ISCIII RETIC REDINREN RD12/0021, PI13/00047, PI15/00298, PIE13/00051, Comunidad de Madrid (CIFRA S2010/BMDâ2378), Sociedad EspaÃ±ola de NefrologÃ­a. Programa IntensificaciÃ³n Actividad Investigadora (ISCIII/Agencia LaÃ­nâEntralgo/CM) to AO, ISCIII Joan Rodes JR14/00028 to BFF and Miguel Servet MS12/03262, MS14/00133, MECD to JP, and Biobanco IISâFJD PT13/0010/0012. All authors have read the journal's policy on disclosure of potential conflicts of interest. The authors confirm that there are no conflicts of interest. All authors have disclosed any financial or personal relationship with organizations that could potentially be perceived as influencing the described research.</p>
    </ack>
    <ref-list content-type="cited-references" id="jcmm12953-bibl-0001">
      <title>References</title>
      <ref id="jcmm12953-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0001">
<string-name>
<surname>Ortiz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>FernandezâFernandez</surname>
<given-names>B</given-names>
</string-name>. <article-title>Humble kidneys predict mighty heart troubles</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2015</year>; <volume>3</volume>: <fpage>489</fpage>â<lpage>91</lpage>.<pub-id pub-id-type="pmid">26028595</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0002">
<collab collab-type="authors">GBD 2013 Mortality and Causes of Death Collaborators</collab>
. <article-title>Global, regional, and national ageâsex specific allâcause and causeâspecific mortality for 240 causes of death, 1990â2013: a systematic analysis for the Global Burden of Disease Study 2013</article-title>. <source>Lancet</source>. <year>2015</year>; <volume>385</volume>: <fpage>117</fpage>â<lpage>71</lpage>.<pub-id pub-id-type="pmid">25530442</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0003">
<collab collab-type="authors">Global Burden of Disease Study 2013 Collaborators</collab>
. <article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â2013: a systematic analysis for the Global Burden of Disease Study 2013</article-title>. <source>Lancet</source>. <year>2015</year>; <volume>386</volume>: <fpage>743</fpage>â<lpage>800</lpage>.<pub-id pub-id-type="pmid">26063472</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0004">
<string-name>
<surname>Ortiz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Covic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fliser</surname>
<given-names>D</given-names>
</string-name>, <italic>et al</italic>
<article-title>Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure</article-title>. <source>Lancet</source>. <year>2014</year>; <volume>383</volume>: <fpage>1831</fpage>â<lpage>43</lpage>.<pub-id pub-id-type="pmid">24856028</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0005">
<string-name>
<surname>Xie</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Perkovic</surname>
<given-names>V</given-names>
</string-name>, <italic>et al</italic>
<article-title>Reninâangiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network metaâanalysis of randomized clinical trials</article-title>. <source>Am J Kidney Dis</source>. <year>2016</year>; <volume>67</volume>: <fpage>728</fpage>â<lpage>41</lpage>.<pub-id pub-id-type="pmid">26597926</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0006">
<string-name>
<surname>FernandezâFernandez</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ortiz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>GomezâGuerrero</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>Therapeutic approaches to diabetic nephropathyâbeyond the RAS</article-title>. <source>Nat Rev Nephrol</source>. <year>2014</year>; <volume>10</volume>: <fpage>325</fpage>â<lpage>46</lpage>.<pub-id pub-id-type="pmid">24802062</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0007">
<string-name>
<surname>Ortiz</surname>
<given-names>A</given-names>
</string-name>. <article-title>Translational nephrology: what translational research is and a bird'sâeye view on translational research in nephrology</article-title>. <source>Clin Kidney J</source>. <year>2015</year>; <volume>8</volume>: <fpage>14</fpage>â<lpage>22</lpage>.<pub-id pub-id-type="pmid">25713705</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0008">
<string-name>
<surname>Barnes</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Glass</surname>
<given-names>WF</given-names>
</string-name>. <article-title>Renal interstitial fibrosis: a critical evaluation of the origin of myofibroblasts</article-title>. <source>Contrib Nephrol</source>. <year>2011</year>; <volume>169</volume>: <fpage>73</fpage>â<lpage>93</lpage>.<pub-id pub-id-type="pmid">21252512</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0009">
<string-name>
<surname>Sanz</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Izquierdo</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>SanchezâNino</surname>
<given-names>MD</given-names>
</string-name>, <italic>et al</italic>
<article-title>TWEAK and the progression of renal disease: clinical translation</article-title>. <source>Nephrol Dial Transplant</source>. <year>2014</year>; <volume>29</volume>(<issue>Suppl 1</issue>): <fpage>i54</fpage>â<lpage>62</lpage>.<pub-id pub-id-type="pmid">24493870</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0010">
<string-name>
<surname>MunozâFelix</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>GonzalezâNunez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>MartinezâSalgado</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>TGFâbeta/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?</article-title>
<source>Pharmacol Ther</source>. <year>2015</year>; <volume>156</volume>: <fpage>44</fpage>â<lpage>58</lpage>.<pub-id pub-id-type="pmid">26493350</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0011">
<string-name>
<surname>SanchezâNino</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Poveda</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sanz</surname>
<given-names>AB</given-names>
</string-name>, <italic>et al</italic>
<article-title>Fn14 in podocytes and proteinuric kidney disease</article-title>. <source>Biochim Biophys Acta</source>. <year>2013</year>; <volume>1832</volume>: <fpage>2232</fpage>â<lpage>43</lpage>.<pub-id pub-id-type="pmid">23999007</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0012">
<string-name>
<surname>Sanz</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Justo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>SanchezâNino</surname>
<given-names>MD</given-names>
</string-name>, <italic>et al</italic>
<article-title>The cytokine TWEAK modulates renal tubulointerstitial inflammation</article-title>. <source>J Am Soc Nephrol</source>. <year>2008</year>; <volume>19</volume>: <fpage>695</fpage>â<lpage>703</lpage>.<pub-id pub-id-type="pmid">18235096</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0013">
<string-name>
<surname>Ucero</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>BenitoâMartin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>FuentesâCalvo</surname>
<given-names>I</given-names>
</string-name>, <italic>et al</italic>
<article-title>TNFârelated weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Rasâdependent proliferation of cultured renal fibroblast</article-title>. <source>Biochim Biophys Acta</source>. <year>2013</year>; <volume>1832</volume>: <fpage>1744</fpage>â<lpage>55</lpage>.<pub-id pub-id-type="pmid">23748045</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0014">
<string-name>
<surname>Walker</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Volkmuth</surname>
<given-names>W</given-names>
</string-name>. <article-title>Cell adhesion and matrix remodeling genes identified by coâexpression analysis</article-title>. <source>Gene Function &amp; Disease</source>. <year>2002</year>; <volume>3</volume>: <fpage>109</fpage>â<lpage>12</lpage>.</mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0015">
<string-name>
<surname>Gabrielsen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lawler</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Yongzhong</surname>
<given-names>W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium</article-title>. <source>J Mol Cell Cardiol</source>. <year>2007</year>; <volume>42</volume>: <fpage>870</fpage>â<lpage>83</lpage>.<pub-id pub-id-type="pmid">17343875</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0016">
<string-name>
<surname>Chondrogianni</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>de</surname>
<given-names>CMS</given-names>
</string-name>, <string-name>
<surname>Franceschi</surname>
<given-names>C</given-names>
</string-name>, <italic>et al</italic>
<article-title>Cloning of differentially expressed genes in skin fibroblasts from centenarians</article-title>. <source>Biogerontology</source>. <year>2004</year>; <volume>5</volume>: <fpage>401</fpage>â<lpage>9</lpage>.<pub-id pub-id-type="pmid">15609104</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0017">
<string-name>
<surname>Poveda</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>SanchezâNino</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Glorieux</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>pâcresyl sulphate has proâinflammatory and cytotoxic actions on human proximal tubular epithelial cells</article-title>. <source>Nephrol Dial Transplant</source>. <year>2014</year>; <volume>29</volume>: <fpage>56</fpage>â<lpage>64</lpage>.<pub-id pub-id-type="pmid">24166466</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0018">
<string-name>
<surname>FernandezâSanchez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Berzal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>SanchezâNino</surname>
<given-names>MD</given-names>
</string-name>, <italic>et al</italic>
<article-title>AG490 promotes HIFâ1alpha accumulation by inhibiting its hydroxylation</article-title>. <source>Curr Med Chem</source>. <year>2012</year>; <volume>19</volume>: <fpage>4014</fpage>â<lpage>23</lpage>.<pub-id pub-id-type="pmid">22709000</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0019">
<string-name>
<surname>Ortiz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lorz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Catalan</surname>
<given-names>MP</given-names>
</string-name>, <italic>et al</italic>
<article-title>Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure</article-title>. <source>Kidney Int</source>. <year>2000</year>; <volume>57</volume>: <fpage>969</fpage>â<lpage>81</lpage>.<pub-id pub-id-type="pmid">10720950</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0020">
<string-name>
<surname>Asmann</surname>
<given-names>YW</given-names>
</string-name>, <string-name>
<surname>Necela</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Kalari</surname>
<given-names>KR</given-names>
</string-name>, <italic>et al</italic>
<article-title>Detection of redundant fusion transcripts as biomarkers or diseaseâspecific therapeutic targets in breast cancer</article-title>. <source>Cancer Res</source>. <year>2012</year>; <volume>72</volume>: <fpage>1921</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">22496456</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0021">
<string-name>
<surname>Hodgin</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Borczuk</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Nasr</surname>
<given-names>SH</given-names>
</string-name>, <italic>et al</italic>
<article-title>A molecular profile of focal segmental glomerulosclerosis from formalinâfixed, paraffinâembedded tissue</article-title>. <source>Am J Pathol</source>. <year>2010</year>; <volume>177</volume>: <fpage>1674</fpage>â<lpage>86</lpage>.<pub-id pub-id-type="pmid">20847290</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0022">
<string-name>
<surname>Izquierdo</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Sanz</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Mezzano</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>TWEAK (tumor necrosis factorâlike weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation</article-title>. <source>Kidney Int</source>. <year>2012</year>; <volume>81</volume>: <fpage>1098</fpage>â<lpage>107</lpage>.<pub-id pub-id-type="pmid">22278019</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0023">
<string-name>
<surname>LopezâHernandez</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>LopezâNovoa</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Role of TGFâbeta in chronic kidney disease: an integration of tubular, glomerular and vascular effects</article-title>. <source>Cell Tissue Res</source>. <year>2012</year>; <volume>347</volume>: <fpage>141</fpage>â<lpage>54</lpage>.<pub-id pub-id-type="pmid">22105921</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0024">
<string-name>
<surname>Buckanovich</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Sasaroli</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>O'BrienâJenkins</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Tumor vascular proteins as biomarkers in ovarian cancer</article-title>. <source>J Clin Oncol</source>. <year>2007</year>; <volume>25</volume>: <fpage>852</fpage>â<lpage>61</lpage>.<pub-id pub-id-type="pmid">17327606</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0025">
<string-name>
<surname>Xiong</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in nonâsmall cell lung carcinoma from Chinese patients</article-title>. <source>Carcinogenesis</source>. <year>2012</year>; <volume>33</volume>: <fpage>1797</fpage>â<lpage>805</lpage>.<pub-id pub-id-type="pmid">22696596</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0026">
<string-name>
<surname>Wang</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>HW</given-names>
</string-name>, <italic>et al</italic>
<article-title>Identification of MXRA5 as a novel biomarker in colorectal cancer</article-title>. <source>Oncol Lett</source>. <year>2013</year>; <volume>5</volume>: <fpage>544</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">23420087</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0027">
<string-name>
<surname>Lorz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Benito</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ucero</surname>
<given-names>AC</given-names>
</string-name>, <italic>et al</italic>
<article-title>Trail and kidney disease</article-title>. <source>Front Biosci (Landmark Ed)</source>. <year>2009</year>; <volume>14</volume>: <fpage>3740</fpage>â<lpage>9</lpage>.<pub-id pub-id-type="pmid">19273307</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0028">
<string-name>
<surname>Lorz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>BenitoâMartin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Boucherot</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>The death ligand TRAIL in diabetic nephropathy</article-title>. <source>J Am Soc Nephrol</source>. <year>2008</year>; <volume>19</volume>: <fpage>904</fpage>â<lpage>14</lpage>.<pub-id pub-id-type="pmid">18287563</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0029">
<string-name>
<surname>RodriguezâIturbe</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>HerreraâAcosta</surname>
<given-names>J</given-names>
</string-name>. <article-title>Tubulointerstitial damage and progression of renal failure</article-title>. <source>Kidney Int Suppl</source>. <year>2005</year>; <volume>99</volume>: <fpage>S82</fpage>â<lpage>6</lpage>.</mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0030">
<string-name>
<surname>Gewin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zent</surname>
<given-names>R</given-names>
</string-name>. <article-title>How does TGFâbeta mediate tubulointerstitial fibrosis?</article-title>
<source>Semin Nephrol</source>. <year>2012</year>; <volume>32</volume>: <fpage>228</fpage>â<lpage>35</lpage>.<pub-id pub-id-type="pmid">22835453</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0031">
<string-name>
<surname>Zeisberg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Neilson</surname>
<given-names>EG</given-names>
</string-name>. <article-title>Mechanisms of tubulointerstitial fibrosis</article-title>. <source>J Am Soc Nephrol</source>. <year>2010</year>; <volume>21</volume>: <fpage>1819</fpage>â<lpage>34</lpage>.<pub-id pub-id-type="pmid">20864689</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0032">
<string-name>
<surname>Leask</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Abraham</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>TGFâbeta signaling and the fibrotic response</article-title>. <source>FASEB J</source>. <year>2004</year>; <volume>18</volume>: <fpage>816</fpage>â<lpage>27</lpage>.<pub-id pub-id-type="pmid">15117886</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0033">
<string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>. <article-title>New insights into epithelialâmesenchymal transition in kidney fibrosis</article-title>. <source>J Am Soc Nephrol</source>. <year>2010</year>; <volume>21</volume>: <fpage>212</fpage>â<lpage>22</lpage>.<pub-id pub-id-type="pmid">20019167</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0034">
<string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Renal fibrosis: new insights into the pathogenesis and therapeutics</article-title>. <source>Kidney Int</source>. <year>2006</year>; <volume>69</volume>: <fpage>213</fpage>â<lpage>7</lpage>.<pub-id pub-id-type="pmid">16408108</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0035">
<string-name>
<surname>Shull</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Ormsby</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kier</surname>
<given-names>AB</given-names>
</string-name>, <italic>et al</italic>
<article-title>Targeted disruption of the mouse transforming growth factorâbeta 1 gene results in multifocal inflammatory disease</article-title>. <source>Nature</source>. <year>1992</year>; <volume>359</volume>: <fpage>693</fpage>â<lpage>9</lpage>.<pub-id pub-id-type="pmid">1436033</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0036">
<string-name>
<surname>SanchezâNino</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Bozic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>CordobaâLanus</surname>
<given-names>E</given-names>
</string-name>, <italic>et al</italic>
<article-title>Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy</article-title>. <source>Am J Physiol Renal Physiol</source>. <year>2012</year>; <volume>302</volume>: <fpage>F647</fpage>â<lpage>57</lpage>.<pub-id pub-id-type="pmid">22169009</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0037">
<string-name>
<surname>SanchezâNino</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Sanz</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Carrasco</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy</article-title>. <source>Nephrol Dial Transplant</source>. <year>2011</year>; <volume>26</volume>: <fpage>1797</fpage>â<lpage>802</lpage>.<pub-id pub-id-type="pmid">20504837</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0038">
<string-name>
<surname>MorgadoâPascual</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>RayegoâMateos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Valdivielso</surname>
<given-names>JM</given-names>
</string-name>, <italic>et al</italic>
<article-title>Paricalcitol inhibits aldosteroneâinduced proinflammatory factors by modulating epidermal growth factor receptor pathway in cultured tubular epithelial cells</article-title>. <source>Biomed. Res. Int</source>. <year>2015</year>; <volume>2015</volume>: <fpage>783538</fpage>.<pub-id pub-id-type="pmid">26064952</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0039">
<string-name>
<surname>Park</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>IJ</given-names>
</string-name>, <italic>et al</italic>
<article-title>Renoprotective effects of paricalcitol on gentamicinâinduced kidney injury in rats</article-title>. <source>Am J Physiol Renal Physiol</source>. <year>2010</year>; <volume>298</volume>: <fpage>301</fpage>â<lpage>13</lpage>.</mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0040">
<string-name>
<surname>Tan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy</article-title>. <source>J Am Soc Nephrol</source>. <year>2006</year>; <volume>17</volume>: <fpage>3382</fpage>â<lpage>93</lpage>.<pub-id pub-id-type="pmid">17082242</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0041">
<string-name>
<surname>PerezâGomez</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>OrtizâArduan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>LorenzoâSellares</surname>
<given-names>V</given-names>
</string-name>. <article-title>Vitamin D and proteinuria: a critical review of molecular bases and clinical experience</article-title>. <source>Nefrologia</source>. <year>2013</year>; <volume>33</volume>: <fpage>716</fpage>â<lpage>26</lpage>.<pub-id pub-id-type="pmid">24089164</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0042">
<string-name>
<surname>Gonzales</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Pisitkun</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hoffert</surname>
<given-names>JD</given-names>
</string-name>, <italic>et al</italic>
<article-title>Largeâscale proteomics and phosphoproteomics of urinary exosomes</article-title>. <source>J Am Soc Nephrol</source>. <year>2009</year>; <volume>20</volume>: <fpage>363</fpage>â<lpage>79</lpage>.<pub-id pub-id-type="pmid">19056867</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0043">
<string-name>
<surname>Zou</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Selaru</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon</article-title>. <source>Oncogene</source>. <year>2002</year>; <volume>21</volume>: <fpage>4855</fpage>â<lpage>62</lpage>.<pub-id pub-id-type="pmid">12101425</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0044">
<string-name>
<surname>Su</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Cooke</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Ching</surname>
<given-names>KA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Largeâscale analysis of the human and mouse transcriptomes</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2002</year>; <volume>99</volume>: <fpage>4465</fpage>â<lpage>70</lpage>.<pub-id pub-id-type="pmid">11904358</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0045">
<string-name>
<surname>Cutcliffe</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kersey</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>CC</given-names>
</string-name>, <italic>et al</italic>
<article-title>Clear cell sarcoma of the kidney: upâregulation of neural markers with activation of the sonic hedgehog and Akt pathways</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>; <volume>11</volume>: <fpage>7986</fpage>â<lpage>94</lpage>.<pub-id pub-id-type="pmid">16299227</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0046">
<string-name>
<surname>Woroniecka</surname>
<given-names>KI</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Mohtat</surname>
<given-names>D</given-names>
</string-name>, <italic>et al</italic>
<article-title>Transcriptome analysis of human diabetic kidney disease</article-title>. <source>Diabetes</source>. <year>2011</year>; <volume>60</volume>: <fpage>2354</fpage>â<lpage>69</lpage>.<pub-id pub-id-type="pmid">21752957</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0047">
<string-name>
<surname>Berthier</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Bethunaickan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>GonzalezâRivera</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Crossâspecies transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis</article-title>. <source>J Immunol</source>. <year>2012</year>; <volume>189</volume>: <fpage>988</fpage>â<lpage>1001</lpage>.<pub-id pub-id-type="pmid">22723521</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0048">
<string-name>
<surname>Schmid</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Boucherot</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yasuda</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Modular activation of nuclear factorâkappaB transcriptional programs in human diabetic nephropathy</article-title>. <source>Diabetes</source>. <year>2006</year>; <volume>55</volume>: <fpage>2993</fpage>â<lpage>3003</lpage>.<pub-id pub-id-type="pmid">17065335</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0049">
<string-name>
<surname>Ju</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Greene</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Eichinger</surname>
<given-names>F</given-names>
</string-name>, <italic>et al</italic>
<article-title>Defining cellâtype specificity at the transcriptional level in human disease</article-title>. <source>Genome Res</source>. <year>2013</year>; <volume>23</volume>: <fpage>1862</fpage>â<lpage>73</lpage>.<pub-id pub-id-type="pmid">23950145</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0050">
        <label>50</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0050">
<string-name>
<surname>Flechner</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Kurian</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Head</surname>
<given-names>SR</given-names>
</string-name>, <italic>et al</italic>
<article-title>Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes</article-title>. <source>Am J Transplant</source>. <year>2004</year>; <volume>4</volume>: <fpage>1475</fpage>â<lpage>89</lpage>.<pub-id pub-id-type="pmid">15307835</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0051">
        <label>51</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0051">
<string-name>
<surname>Neusser</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Lindenmeyer</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Moll</surname>
<given-names>AG</given-names>
</string-name>, <italic>et al</italic>
<article-title>Human nephrosclerosis triggers a hypoxiaârelated glomerulopathy</article-title>. <source>Am J Pathol</source>. <year>2010</year>; <volume>176</volume>: <fpage>594</fpage>â<lpage>607</lpage>.<pub-id pub-id-type="pmid">20019191</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm12953-bib-0052">
        <label>52</label>
        <mixed-citation publication-type="journal" id="jcmm12953-cit-0052">
<string-name>
<surname>Lenburg</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Liou</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Gerry</surname>
<given-names>NP</given-names>
</string-name>, <italic>et al</italic>
<article-title>Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data</article-title>. <source>BMC Cancer</source>. <year>2003</year>; <volume>3</volume>: <fpage>31</fpage>.<pub-id pub-id-type="pmid">14641932</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>